Phase 1 of the CFP Weight Loss Protocol, known as Fat Loading, sets the metabolic foundation for lasting transformation. Rather than jumping straight into calorie restriction, this 10-14 day preparatory window strategically increases healthy fat intake while introducing low-dose tirzepatide. The goal is to restore leptin sensitivity, reduce systemic inflammation, and prime mitochondria for efficient fat oxidation before entering the aggressive fat-loss Phase 2.
Russell Clark’s clinical approach challenges the outdated CICO model by focusing on hormonal signaling. High-quality fats during this phase help recalibrate GIP and GLP-1 pathways, quiet hunger signals, and lower CRP levels that often block fat release. Patients frequently report improved energy, mental clarity, and reduced cravings within days.
Understanding the Science Behind Fat Loading
Research shows that sudden caloric deficits without metabolic preparation trigger protective responses: lowered BMR, elevated cortisol, and leptin resistance. By contrast, a controlled fat-loading period signals abundance to the brain, improving leptin sensitivity so the “I am full” message is heard again.
Tirzepatide’s dual agonism of GLP-1 and GIP receptors plays a central role. GIP enhances lipid metabolism and appears to improve the tolerability of GLP-1 effects, reducing nausea while amplifying satiety. Studies on tirzepatide demonstrate superior body composition improvements compared to GLP-1 agonists alone, with greater preservation of lean muscle and deeper reductions in visceral fat.
An anti-inflammatory protocol is non-negotiable. Eliminating lectins, refined carbohydrates, and processed seed oils lowers hs-CRP, allowing fat cells to release stored energy rather than hoard it. Nutrient-dense, low-lectin vegetables such as bok choy provide volume, fiber, and micronutrients without triggering immune responses that impair mitochondrial efficiency.
Clinical Markers That Guide Phase 1 Success
Before starting, Clark’s protocol requires baseline testing: fasting insulin, glucose (to calculate HOMA-IR), hs-CRP, body composition analysis, and subjective hunger logs. Ideal candidates show elevated HOMA-IR and CRP, indicating chronic inflammation and insulin resistance.
During Fat Loading, patients track emerging ketones as the body shifts toward fat metabolism. Even modest ketosis signals improved mitochondrial efficiency and reduced oxidative stress. Repeat labs at the end of Phase 1 typically reveal dropping CRP and stabilizing blood glucose—early proof the metabolic reset is underway.
Body composition takes precedence over scale weight. A modest increase or maintenance of scale weight during this phase is common and desirable if it reflects increased subcutaneous water and improved cellular hydration rather than fat gain. The real metric is the shift in fat-to-muscle ratio.
Practical Implementation: Russell Clark’s Day-to-Day Framework
Fat Loading centers on 60-70% calories from healthy fats (avocado, olive oil, coconut oil, fatty fish, macadamia nuts) paired with moderate protein and minimal carbohydrates. A typical day might include scrambled eggs cooked in ghee with spinach and bok choy, grilled salmon with olive oil dressing, and a small handful of berries.
Tirzepatide is introduced via subcutaneous injection at the lowest effective dose—often 0.25–0.5 mg—twice weekly. Proper injection technique and site rotation prevent lipohypertrophy. Patients are advised to consume fats with the medication to further buffer any initial GI side effects.
Hydration, electrolytes, and targeted supplementation (including Vitamin C for mitochondrial membrane support) round out the protocol. Light resistance training two to three times weekly helps preserve muscle and supports BMR. Sleep optimization is equally critical; poor sleep negates leptin sensitivity gains.
Many following the 30-Week Tirzepatide Reset use this Phase 1 template repeatedly between more aggressive cycles, preventing the metabolic slowdown commonly seen with continuous GLP-1 use.
Addressing Common Questions About Phase 1
Will I gain weight during Fat Loading? Temporary scale increases of 1–3 pounds often reflect glycogen replenishment and water retention. Body composition scans usually show stable or slightly reduced fat mass.
How do I know if I’m ready for Phase 2? Clinical signs include normalized hunger, improved energy, measurable drop in hs-CRP, and the appearance of mild ketones. Most patients transition after 10–14 days.
Is this approach safe long-term? When cycled properly within the 70-day structure (Phase 1 → Phase 2 Aggressive Loss → Maintenance Phase), the protocol minimizes risks of muscle loss, BMR decline, and rebound weight gain associated with continuous caloric restriction or lifelong medication dependence.
Can I follow this without tirzepatide? While medication accelerates hormonal recalibration, the nutritional framework—lectin-free, nutrient-dense, anti-inflammatory—still produces meaningful improvements in metabolic flexibility and CRP reduction.
Moving Into Lasting Metabolic Health
Phase 1 is not a standalone diet but the critical on-ramp to the full CFP Weight Loss Protocol. By restoring mitochondrial efficiency, leptin sensitivity, and proper GIP/GLP-1 signaling, the body becomes primed to burn stored fat aggressively in Phase 2 and maintain new set points during the 28-day Maintenance Phase.
The ultimate outcome is a true metabolic reset: lower HOMA-IR, improved body composition, stable energy, and freedom from constant hunger. Patients who master Fat Loading report not only dramatic physical changes but a fundamental shift in how their bodies communicate about food and energy.
Success depends on precision. Track biomarkers, prioritize food quality over calories, and respect the hormonal choreography that governs fat storage and release. When executed as designed, Phase 1 transforms a standard weight-loss attempt into a clinically guided metabolic transformation that lasts.
The research is clear: addressing inflammation, optimizing incretin hormones, and preparing mitochondria before aggressive loss produces superior, sustainable results compared to traditional CICO approaches. Russell Clark’s protocol offers a roadmap grounded in both emerging pharmacology and time-tested metabolic principles.